COVID-19 Treatment: The Race Against Time

被引：10
作者：
Aljofan, Mohamad [1 ]
Gaipov, Abduzhappar [2 ]
机构：
[1] Nazarbayev Univ, Sch Med, Dept Biomed Sci, Nur Sultan, Kazakhstan
[2] Nazarbayev Univ, Sch Med, Dept Clin Sci, Nur Sultan, Kazakhstan
来源：
ELECTRONIC JOURNAL OF GENERAL MEDICINE | 2020年 / 17卷 / 06期
关键词：
COVID-19; treatment; clinical trials; Chloroquine; Lopinavir-ritonavir; Remdesivir; Tocilizumab; Camostat mesilate; PROTEASE INHIBITOR; TOCILIZUMAB; RECEPTOR; SARS;
D O I：
10.29333/ejgm/7890
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The new outbreak of the novel coronavirus infection emerged in Wuhan- China in late 2019, by the end of Mar 2020, it has spread in more than 178 countries and territories. There is no vaccine or antiviral treatment for COVID-19. Currently, there are several drugs and vaccines being tested for their potential activity against the disease. In this review, we briefly discuss some of the investigational drugs and vaccines being tested against COVID-19 as well as their potential drawbacks.
引用
收藏
页数：3
相关论文
共 17 条
[1]   Chloroquine and COVID-19: A Light at the End of the Tunnel, or is it Another Train? [J].
Aljofan, Mohamad ;
Gaipov, Abduzhappar .
ELECTRONIC JOURNAL OF GENERAL MEDICINE, 2020, 17 (04)
[2]  
[Anonymous], 2020, Int J Res Pharm Sci.
[3]  
Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
[4]  
Chinese Clinical Trial Registry, 2020, MULT RAND CONTR TRIA
[5]   New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections [J].
De Clercq, Erik .
CHEMISTRY-AN ASIAN JOURNAL, 2019, 14 (22) :3962-3968
[6]   SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [J].
Hoffmann, Markus ;
Kleine-Weber, Hannah ;
Schroeder, Simon ;
Krueger, Nadine ;
Herrler, Tanja ;
Erichsen, Sandra ;
Schiergens, Tobias S. ;
Herrler, Georg ;
Wu, Nai-Huei ;
Nitsche, Andreas ;
Mueller, Marcel A. ;
Drosten, Christian ;
Poehlmann, Stefan .
CELL, 2020, 181 (02) :271-+
[7]   Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus [J].
Li, WH ;
Moore, MJ ;
Vasilieva, N ;
Sui, JH ;
Wong, SK ;
Berne, MA ;
Somasundaran, M ;
Sullivan, JL ;
Luzuriaga, K ;
Greenough, TC ;
Choe, H ;
Farzan, M .
NATURE, 2003, 426 (6965) :450-454
[8]   Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate [J].
Maini, R. N. ;
Taylor, P. C. ;
Szechinski, J. ;
Pavelka, K. ;
Broell, J. ;
Balint, G. ;
Emery, P. ;
Raemen, F. ;
Petersen, J. ;
Smolen, J. ;
Thomson, D. ;
Kishimoto, T. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2817-2829
[9]   A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics [J].
Mulangu, Sabue ;
Dodd, Lori E. ;
Davey, Richard T., Jr. ;
Mbaya, Olivier Tshiani ;
Proschan, Michael ;
Mukadi, Daniel ;
Manzo, Mariano Lusakibanza ;
Nzolo, Didier ;
Oloma, Antoine Tshomba ;
Ibanda, Augustin ;
Ali, Rosine ;
Coulibaly, Sinare ;
Levine, Adam C. ;
Grais, Rebecca ;
Diaz, Janet ;
Lane, H. Clifford ;
Muyembe-Tamfum, Jean-Jacques ;
Sivahera, Billy ;
Camara, Modet ;
Kojan, Richard ;
Walker, Robert ;
Dighero-Kemp, Bonnie ;
Cao, Huyen ;
Mukumbayi, Philippe ;
Mbala-Kingebeni, Placide ;
Ahuka, Steve ;
Albert, Sarah ;
Bonnett, Tyler ;
Crozier, Ian ;
Duvenhage, Michael ;
Proffitt, Calvin ;
Teitelbaum, Marc ;
Moench, Thomas ;
Aboulhab, Jamila ;
Barrett, Kevin ;
Cahill, Kelly ;
Cone, Katherine ;
Eckes, Risa ;
Hensley, Lisa ;
Herpin, Betsey ;
Higgs, Elizabeth ;
Ledgerwood, Julie ;
Pierson, Jerome ;
Smolskis, Mary ;
Sow, Ydrissa ;
Tierney, John ;
Sivapalasingam, Sumathi ;
Holman, Wendy ;
Gettinger, Nikki ;
Vallee, David .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (24) :2293-2303
[10]   Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers [J].
Park, S. Y. ;
Lee, J. S. ;
Son, J. S. ;
Ko, J. H. ;
Peck, K. R. ;
Jung, Y. ;
Woo, H. J. ;
Joo, Y. S. ;
Eom, J. S. ;
Shi, H. .
JOURNAL OF HOSPITAL INFECTION, 2019, 101 (01) :42-46
12